Grace
Discovering Drugs using Artificial Intelligence
Company Overview
Snapshot
Founded in January 2025 by David Futorian, Grace operates with 1–10 employees and is currently in the R&D product stage. The company is leveraging AI to address challenges in drug development, a strategic move highlighted by the launch of the startup in January 2025 by former Verbit CEO Tom Livne.
Business overview
Grace is a Health Tech & Life Sciences company focused on drug discovery through the application of Artificial Intelligence. The company is developing core AI technology to tackle complex challenges within the drug development lifecycle, serving the pharmaceutical and medical biotechnology sectors, as well as the broader digital healthcare market.
Strategic signal
In January 2025, Grace launched with a focus on leveraging AI for drug development, a significant move for the Health Tech & Life Sciences sector. This launch, led by former Verbit CEO Tom Livne, signals a strong intent to innovate in a capital-intensive industry, indicating potential for rapid advancement in pharmaceutical research and development.
Log in to access full profile ›Company Intelligence Q&A
- When was Grace founded?
- Grace was founded in January 2025.
- Who are the co-founders of Grace?
- David Futorian is a co-founder of Grace. Tom Livne and Shay Liraz are also co-founders.
- What is Grace's primary focus?
- Grace is focused on discovering drugs using Artificial Intelligence to address challenges in drug development.
- What is the current product stage of Grace?
- Grace is currently in the R&D product stage, focusing on developing core AI technology to tackle complex challenges within the drug development lifecycle.
- What significant event occurred in January 2025 for Grace?
- In January 2025, former Verbit CEO Tom Livne launched Grace, a new startup leveraging AI to tackle drug development challenges.